Recently, PPD, the clinical development and analysis service brand of Thermo Fisher Scientific (hereinafter referred to as: Thermo Fisher), a global leader in enabling scientific and technological progress, and Beijing Gaobo Medical Technology Group Co., LTD. (hereinafter referred to as: Gab Medical Group signed a memorandum of strategic cooperation at Beijing Gab Hospital, in which the two parties will commit to cooperation in clinical research and jointly promote the high-quality development of Chinese medicine and global development. The strategic cooperation will rely on the globalization advantages brought by PPD’s global research center network, focus on improving the quality of clinical research, promote global cooperation and collaboration in early clinical development, and better serve the high-quality development and global development of Chinese medicine.

Thermo Field and Cobb Medical Group reached a strategic cooperation

With the continuous upgrading of China’s pharmaceutical industry structure and the continuous development of pharmaceutical innovation, internationalization has become the development trend of China’s innovative pharmaceutical enterprises, and domestic research centers have also been more deeply involved in global research and development. Through this cooperation, the two sides will more effectively use their respective advantages of resources, with global high-quality standards and knowledge and experience to help the development of medicine in China and the world, accelerate drug innovation, and benefit more patients.

853-049542-173

Hann Pang, President of Thermo Fly China, said: “Thermo Fly is long-term optimistic about the development prospects of innovative medicine in China, and has always adhered to the local development strategy of ‘creating and co-living’ in China. Through cutting-edge technologies, global resources and a full range of pharmaceutical services, Thermo Fei will work with Chinese pharmaceutical companies to continue to promote pharmaceutical innovation and research, accelerate the pace of global development of local companies, and help build a healthier, cleaner and safer future.”

Zheng Xiaoyu, Vice President of Gao Bo Medical Group and Executive President of Beijing Gao Bo Hospital, said: “It is a great honor to enter into a strategic cooperation with PPD under Thermo Field, and both parties share a common vision and a consistent desire to cooperate in the field of clinical research. We will leverage PPD’s global early-stage clinical research capabilities and experience to further enhance early-stage clinical research capacity, jointly address challenges, accelerate high-quality clinical research development, and benefit more patients.”

PPD, Thermo Feld’s clinical development and analysis services brand, is the world’s leading pharmaceutical research and development outsourcing service organization (CRO), providing comprehensive integrated drug development, laboratory and lifecycle management services to customers and partners including pharmaceutical, biotechnology, medical devices, academic institutions and government organizations. PPD is currently in clinical trials in more than 100 countries. We help our customers and partners reduce the cost and time of drug development, optimize value, and develop innovative, effective, and safe medical products with innovative, cutting-edge technology, therapeutic expertise, and a strong commitment to quality.